Loading…
← CockpitCompetitor Analysis › 000950.SZ C.Q. Pharmaceutical Holding Co., Ltd. Class AOpen in the cockpit ↗

C.Q. Pharmaceutical Holding Co., Ltd. Class A000950.SZCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major

Chongqing-based pharmaceutical holding company selling drugs and health products in China.

Momentum neutral 55
Mkt cap
$1.24B
US dollars, full cap
Free float
34%
of shares outstanding
$/day
$10.4M
20-day average traded
Fwd P/E
18.6×
forward earnings
ROIC−WACC
-3.3 pp
WACC 5.0%
Hurdle
n/a
no reverse DCF
Next earnings
159 days
26 Apr 2027
Close · CNYCN¥4.88
1D-0.2%
1W-3.8%
1M-5.1%
3M-14.7%
6M-26.9%
YTD-16.1%
1Y-9.6%
ATR %1.9%
52w lowhigh34.1% off high

What C.Q. Pharmaceutical does

Chongqing-based pharmaceutical holding company selling drugs and health products in China.

Where it sits in the supply chain

  • Pharmaceuticals
  • Generics/holding

Moat: none

Headquarters: Chongqing, China · Employees: 12,237

C.Q. Pharmaceutical at a glance

Size C.Q. Pharmaceutical (000950.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $1.24B, the 1796th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥4.88 on 18 Nov 2026.

Performance Over six months the shares fell 26.9%, against -16.4% for the median peer and -20.0% for the China market (cap-weighted) — 6th lowest of 21 in its peer set.

Growth Revenue fell 3.1% over the last twelve months (peer median +5.3%); the operating margin is 0.8% (peer median -2.0%).

Valuation It trades at 18.6× forward earnings against a peer median of 24.0× (5th cheapest of 11).

Capital Return on invested capital runs 3.3 points below its cost of capital (5.0% WACC).

Next results Next results expected around 26 Apr 2027 (exchange calendar; dates can move).

Relative performance

8010021 May 202621 Aug 202618 Nov 2026Peer median 85000950.SZ 76
Six months, rebased to 100: C.Q. Pharmaceutical against the median of its 20 peers (local-currency closes).

C.Q. Pharmaceutical financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥80.5BCN¥82.3BCN¥80.5BCN¥78.3BCN¥67.7B
Revenue growth—+2%+3%+16%—
Gross profitCN¥5.62BCN¥5.40BCN¥5.47BCN¥5.73BCN¥5.36B
EBITDAn/aCN¥1.54BCN¥1.78BCN¥2.35BCN¥2.64B
Net incomeCN¥323MCN¥387MCN¥283MCN¥625MCN¥952M
Free cash flow-CN¥501MCN¥544M-CN¥371MCN¥300MCN¥40.9M
Capital expenditureCN¥328MCN¥300MCN¥251MCN¥244MCN¥268M
Total debtCN¥29.7BCN¥28.1BCN¥28.9BCN¥27.2BCN¥27.2B

Quarterly statements and history in the cockpit →

C.Q. Pharmaceutical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%-25%0%+25%+50%-10%0%+10%GPCR688076GHRSAVLN300204IDIAAMPH347850002332HROW26163000062493301263LBRX688321OCULINVAMNKD000950.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. C.Q. Pharmaceutical is the large dot.

Fundamentals: revenue growth against valuation

-20%0%+20%0×200×400×688076300204300026AMPH002332HROW301263688321MNKD000950.SZRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. C.Q. Pharmaceutical is the large dot.

C.Q. Pharmaceutical competitors and peer comparison

How C.Q. Pharmaceutical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

C.Q. Pharmaceutical against its 20 peers (data as of 18 Nov 2026)
Measure000950.SZPeer medianRank in peer set
1-month return-5.1%-5.4%10th highest of 21
6-month return-26.9%-16.4%6th lowest of 21
Distance from 52-week high-34.1%-41.7%7th highest of 21
Revenue growth (TTM)-3.1%+5.3%7th lowest of 17
Operating margin0.8%-2.0%7th highest of 17
Forward P/E18.6×24.0×5th cheapest of 11
ROIC minus cost of capital-3.3 pp-6.1 pp5th highest of 15

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
C.Q. Pharmaceutical 000950.SZChina$1.24B-27%-3%1%18.6×n/an/a
Structure Therapeutics, Inc. Sponsored ADR GPCRUnited States$1.24B-53%n/an/an/an/an/a
Sinopep-Allsino Bio Pharmaceutical 688076.SSChina$1.25B-16%+14%19%11.9×3.4%+27.9%
GH Research GHRSUnited States$1.25B-19%n/an/an/an/an/a
Avalyn Pharma AVLNUnited States$1.23B-1%n/an/an/an/an/a
Staidson (Beijing) Biopharmaceuticals 300204.SZChina$1.26B-41%-24%-51%522.3×n/an/a
Tianjin Chase Sun Pharmaceutical 300026.SZChina$1.23B-10%-29%3%21.3×7.0%-5.3%
Idorsia IDIA.SWSwitzerland$1.22B-9%-5%-70%n/an/an/a
Amphastar Pharmaceuticals AMPHUnited States$1.27B+64%+3%19%9.1×2.5%+15.5%
D&D Pharmatech 347850.KSSouth Korea$1.22B-49%-77%-2,324%n/an/an/a
Zhejiang Xianju Pharmaceutical 002332.SZChina$1.28B-1%+8%11%17.7×-0.4%-1.3%
Harrow HROWUnited States$1.21B+4%+21%1%26.8×n/an/a
CStone Pharmaceuticals 2616.HKHong Kong$1.21B-22%+117%-89%n/an/an/a
Chongqing Lummy Pharmaceutical 300006.SZChina$1.21B+26%-6%-19%n/a44.1%-13.2%
Mabwell (Shanghai) Bioscience 2493.HKHong Kong$1.20B-29%+21%-127%n/an/an/a
Guangdong Taienkang Pharmaceutical 301263.SZChina$1.30B-24%+2%-2%60.7×n/an/a
LB Pharmaceuticals LBRXUnited States$1.30B+43%n/an/an/an/an/a
Shenzhen Chipscreen Biosciences 688321.SSChina$1.18B-38%+27%12%60.4×n/an/a
Ocular Therapeutix OCULUnited States$1.31B-26%-10%-681%n/an/an/a
Innoviva INVAUnited States$1.31B-17%+12%38%9.5×-17.2%+3.9%
MannKind MNKDUnited States$1.31B+25%+32%-2%174.4×n/an/a

Questions

Which companies are C.Q. Pharmaceutical's closest peers?
The cockpit's peer set: Structure Therapeutics, Inc. Sponsored ADR (GPCR), Sinopep-Allsino Bio Pharmaceutical (688076.SS), GH Research (GHRS), Avalyn Pharma (AVLN), Staidson (Beijing) Biopharmaceuticals (300204.SZ), Tianjin Chase Sun Pharmaceutical (300026.SZ), Idorsia (IDIA.SW), Amphastar Pharmaceuticals (AMPH).
Is C.Q. Pharmaceutical expensive compared with its peers?
On forward p/e it trades at 18.6× against a peer median of 24.0×, 5th cheapest of 11 in its peer set.
How has C.Q. Pharmaceutical stock performed?
Over six months to 18 Nov 2026 the shares returned -26.9% against -16.4% for the median peer; over one year -9.6%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.